Literature DB >> 9438410

A completely biological tissue-engineered human blood vessel.

N L'Heureux1, S Pâquet, R Labbé, L Germain, F A Auger.   

Abstract

Mechanically challenged tissue-engineered organs, such as blood vessels, traditionally relied on synthetic or modified biological materials for structural support. In this report, we present a novel approach to tissue-engineered blood vessel (TEBV) production that is based exclusively on the use of cultured human cells, i.e., without any synthetic or exogenous biomaterials. Human vascular smooth muscle cells (SMC) cultured with ascorbic acid produced a cohesive cellular sheet. This sheet was placed around a tubular support to produce the media of the vessel. A similar sheet of human fibroblasts was wrapped around the media to provide the adventitia. After maturation, the tubular support was removed and endothelial cells were seeded in the lumen. This TEBV featured a well-defined, three-layered organization and numerous extracellular matrix proteins, including elastin. In this environment, SMC reexpressed desmin, a differentiation marker known to be lost under standard culture conditions. The endothelium expressed von Willebrand factor, incorporated acetylated LDL, produced PGI2, and strongly inhibited platelet adhesion in vitro. The complete vessel had a burst strength over 2000 mmHg. This is the first completely biological TEBV to display a burst strength comparable to that of human vessels. Short-term grafting experiment in a canine model demonstrated good handling and suturability characteristics. Taken together, these results suggest that this novel technique can produce completely biological vessels fulfilling the fundamental requirements for grafting: high burst strength, positive surgical handling, and a functional endothelium.

Entities:  

Mesh:

Year:  1998        PMID: 9438410     DOI: 10.1096/fasebj.12.1.47

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  269 in total

Review 1.  Biologic alternatives to stents and grafts.

Authors:  N M Caplice
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

2.  Characterization of a new tissue-engineered human skin equivalent with hair.

Authors:  M Michel; N L'Heureux; R Pouliot; W Xu; F A Auger; L Germain
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-06       Impact factor: 2.416

Review 3.  Tissue engineering of the vascular system: from capillaries to larger blood vessels.

Authors:  L Germain; M Rémy-Zolghadri; F Auger
Journal:  Med Biol Eng Comput       Date:  2000-03       Impact factor: 2.602

Review 4.  Closer to nature: new biomaterials and tissue engineering in ophthalmology.

Authors:  B Allan
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

Review 5.  Heart valve and arterial tissue engineering.

Authors:  C E Sarraf; A B Harris; A D McCulloch; M Eastwood
Journal:  Cell Prolif       Date:  2003-10       Impact factor: 6.831

Review 6.  Genetic modification of xenografts.

Authors:  J L Platt
Journal:  Curr Top Microbiol Immunol       Date:  2003       Impact factor: 4.291

Review 7.  Designer blood vessels and therapeutic revascularization.

Authors:  Joseph D Berglund; Zorina S Galis
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

Review 8.  Engineering of bypass conduits to improve patency.

Authors:  S T Rashid; H J Salacinski; B J Fuller; G Hamilton; A M Seifalian
Journal:  Cell Prolif       Date:  2004-10       Impact factor: 6.831

9.  Dynamic culture conditions to generate silk-based tissue-engineered vascular grafts.

Authors:  Xiaohui Zhang; Xiuli Wang; Vinny Keshav; Xiaoqin Wang; Jacqueline T Johanas; Gary G Leisk; David L Kaplan
Journal:  Biomaterials       Date:  2009-02-20       Impact factor: 12.479

10.  Assembly of Tissue-Engineered Blood Vessels with Spatially Controlled Heterogeneities.

Authors:  Hannah A Strobel; Tracy A Hookway; Marco Piola; Gianfranco Beniamino Fiore; Monica Soncini; Eben Alsberg; Marsha W Rolle
Journal:  Tissue Eng Part A       Date:  2018-08-20       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.